The androgen receptor of prostate cancer is similar to the estrogen receptor in breast cancer, which may activate the cyclin D-CDK4/6, driving the proliferation of prostate cancer and resistance to hormone manipulation (90).Therefore, this has stimulated the search for CDK4/6 inhibitors. Here, ESR1 is linked to prostate carcinoma.